Spire Healthcare Group (LON:SPI) Rating Reaffirmed
Spire Healthcare Group (LON:SPI) shares have had their “Neutral” Rating kept steady by investment analysts at JP Morgan Cazenove in a very recent research note shared with investors on Friday morning.
From a total of 7 analysts covering Spire Healthcare Group (LON:SPI) stock, 3 rate it a ”Buy”, 0 a “Sell”, and 4 a ”Hold”. This means that 43% of the ratings are positive. The highest target price is GBX 80 while the lowest target price is GBX 27. The mean of all analyst targets is GBX 57.14 with a 6.17% above today’s (GBX 305.8) stock price. Spire Healthcare Group was the topic of 25 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. JP Morgan maintained shares on December 8 with “Neutral” rating. Numis Securities maintained shares with “Add” rating and GBX 390 target share price in a report from an August 21. Berenberg maintained SPI stock in a recent report from November 26 with “Buy” rating. Finally, Jefferies downgraded the stock to “Hold” rating in a report issued on a November 16.
The stock increased 1.49% or GBX 4.5 on December 17, striking GBX 305.8. Approximately 285,847 shares of stock traded hands. Spire Healthcare Group PLC (LON:SPI) has declined 14.82% since May 21, 2015 and is downtrending. It has underperformed by 12.55% the S&P500.
Spire Healthcare Group plc is a United Kingdom independent hospital group offering a range of integrated surgical, medical and diagnostic services. The company has a market cap of 1.25 billion GBP. The Firm provides in-patient, daycase and out-patient care from approximately 39 hospitals, around 13 clinics and one specialist care center across England, Wales and Scotland. It has 23.62 P/E ratio. The Firm also owns and operates a sports medicine, physiotherapy and rehabilitation brand, Perform; a screening service, Lifescan, as well as national pathology services.